Spots Global Cancer Trial Database for Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Official Title: Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL
Study ID: NCT02393157
Study Description
Brief Summary: The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
Detailed Description:
Keywords
Eligibility
Minimum Age: 3 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
New York Medical College, Valhalla, New York, United States
Contact Details
Name: Mitchell Cairo, MD
Affiliation: New York Medical College
Role: STUDY_CHAIR
Name: Matthew Barth, MD
Affiliation: Roswell Park Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
